D-dopa
WikiDoc Resources for D-dopa |
Articles |
---|
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on D-dopa at Clinical Trials.gov Clinical Trials on D-dopa at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on D-dopa
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Directions to Hospitals Treating D-dopa Risk calculators and risk factors for D-dopa
|
Healthcare Provider Resources |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
D-DOPA (Dextrodopa) is similar to L-DOPA (levodopa, 3,4-dihydroxy-L-phenylalanine), but differs in its property of dextrorotation. Levo- and dextro- rotation reference a molecules ability to rotate planes of polarized light in either direction.
While L-Dopa is moderately effective against the loss of natural dopamine in Parkinson's disease, D-Dopa is biologically inactive. D- dopa is L- Dopa's enantiomer. See L-DOPA for more information about DOPA in general.